An oral dosage form of NACA is the subject of an ongoing clinical trial for the treatment of retinitis pigmentosa (Safety and Efficacy of NPI-001 Tablets for RP Associated with Usher Syndrome (SLO RP) (ClinicalTrials.gov Identifier: NCT04355689)). This evidence concerns the gene NACA and Usher syndrome.